What Happened?
Shares of health insurance company Clover Health (NASDAQ: CLOV) jumped 8.5% in the afternoon session after Deutsche Bank initiated coverage on the company with a Buy rating and a $6.00 price target.
Per TipRanks, Deutsche Bank analyst George Hill highlighted several key drivers behind the positive outlook, including Clover Health's growth runway within the Medicare Advantage market, its proprietary Clover Assistant platform, and its non-delegated risk model. The $6.00 price target represents substantial upside compared to the stock's previous closing price of $4.34, boosting investor confidence in the company's operational trajectory.
Is now the time to buy Clover Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Clover Health’s shares are extremely volatile and have had 38 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 10 months ago when the stock dropped 24.2% on the news that the company reported disappointing third-quarter financial results and cut its full-year profitability forecast. While the Medicare-focused company saw its revenue climb by 50.1% compared to the previous year, its earnings per share missed forecasts. Looking ahead, Clover Health lowered its full-year guidance for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to a midpoint of $22.5 million, which was significantly below analysts' expectations and implied a reduction from previous forecasts. The company attributed the weaker outlook to higher-than-expected medical costs and increased healthcare usage trends among its members. This guidance overshadowed its revenue, which beat Wall Street's estimates, as investors focused on the pressure on future profitability.
Clover Health is up 96.9% since the beginning of the year, but at $4.75 per share, it is still trading 12.3% below its 52-week high of $5.41 from June 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Clover Health’s shares 5 years ago would now be looking at only $552.39.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
